Royalty Report: Drugs, Diagnostic, Molecular – Collection: 383569


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Diagnostic
  • Molecular
  • Proteins
  • Disease
  • Therapeutic
  • Hair loss

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 383569

License Grant
Licensor of Switzerland grants the Licensee of Bermuda and the United States an exclusive, even as to Licensor except to the extent necessary to fulfill its obligations under this Agreement, sublicensable, transferable license under the Licensed Patents to Research, Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize Compounds and/or Licensed Products in the Field in the Territory.

Licensor grants a non-exclusive, sublicensable, transferable license under the Licensed Know-How to Research, Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize Compounds and/or Licensed Products in the Field in the Territory.

Licensor grants a non-exclusive, sublicensable, transferable license under the FTO Patents to Research, Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize Compounds and/or Licensed Products in the Territory.

Licensor will use Commercially Reasonable Efforts to transfer to Licensee all items of  Licensed Know-How, including Manufacturing know-how.

For Research, Development, and Manufacturing of Licensed Products Scope & Diligence, Licensee will have sole control and responsibility for the Research, Development, Manufacture and Commercialization of all Licensed Products.

License Property
Licensor has discovered and developed small molecule antagonists to the target known as CRTH2, including the compound known as setipiprant.

Licensor FTO Patents mean any Patents that
— are not Licensor Licensed Patents or Licensor Related Patents;
— cover manufacturing processes, including intermediates, or formulations of Compounds or Licensed Products, or uses of Compounds or Licensed Products for hair growth or the prevention of hair loss; and
—  Licensor or its Affiliates Controls as of the Effective Date or during the Term.

Compounds means
— Licensors compound known as setipiprant ;
— all other compounds covered by the Patents listed; and
— the salts, enantiomers, racemates, polymorphs, crystalline forms, non-crystalline forms, hydrates, solvates, esters, conjugates, metabolites and prodrugs of the compounds.

CRTH2 means
— the gene encoding the chemoattractant receptor-homologous molecule expressed on Th2 cells for any species, which molecule is also known as GPR44 or DP2;
— the protein encoded by such gene; and
— all subtypes, mutants and variants thereof.

CRTH2 Antagonists means any molecule with a primary mechanism of action of antagonizing CRTH2.

Patents are titled/relate to Tetrahydropyridoindole derivatives.

Field of Use
IP is for a novel approach for the treatment of hair loss. Setipiprant is a selective oral antagonist to the prostaglandin D2 (PGD2) receptor. The elevation of PGD2 levels in certain regions of the male scalp is associated with hair loss in those regions.

IPSCIO Record ID: 211864

License Grant
For the Non-Exclusive Research License to Licensor Base Technology, Licensor grants a non-exclusive, world-wide license under the Base Technology to conduct research and development activities pursuant to the Research Plan, with no right to sublicense.   Licensor also grants the right to sublicense or transfer the rights granted under the Collaboration Technology to Affiliates; and to Third Parties.
License Property
License agreement is for the development of orally bioavailable small-molecule compounds identified through the application of PTC’s proprietary GEMS (Gene Expression Modulation by Small Molecules) technology.

GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.

GEMS-UTR (Gene Expression Modulation by Small-Molecules Untranslated Region) is a proprietary screening technology for the identification of small molecules that modulate gene expression by targeting the post-transcriptional control processes that act through the UTRs of mRNA molecules.

The Licensed Product shall mean any Product which incorporates a Collaboration Compound as an active ingredient.  The Collaboration Compound shall mean, on a Target-specific basis, a chemical compound that is synthesized or identified by the Parties, and any metabolites, prodrugs, solvates, including without limitation hydrates, analogs, esters, salts, derivatives, stereoisomers, racemates, tautomers and polymorphs of such chemical compound which are determined to be Active. Collaboration Compound shall include any of a Hit, a Research Compound, a Lead Compound or an IND Candidate.

Field of Use
Field shall mean the prevention, treatment or diagnosis of all diseases or conditions in humans or animals.

This agreement pertains to drug discovery.

IPSCIO Record ID: 383570

License Grant
The University grants to Licensee of Bermuda an exclusive, worldwide right and license, with the right to sublicense, under University Patent Rights to make, have made, use, sell, offer for sale and import Product in the Field of Use during the Term.
License Property
The University owns and controls certain innovative technology for regrowth of hair.

The patents are
— Prostaglandin D2 Synthase and its Products as Cause of Hair Loss and Target for Therapy;
— Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia.

Field of Use
The Field of Use means hair growth and hair removal in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.